ITGAX and neoplasm: Immunogenic cell death, maturation and activation of DCs (CD11c+, CD11c+CD86+, CD11c+MHC-I+), cytotoxic T-lymphocyte anti-tumor immune effects (CD3+, CD3+CD4+ and CD3+CD8+), increased stimulating the transition of T cells to Th1 phenotype.